Mainz Biomed B.V. (MYNZ) News
Filter MYNZ News Items
MYNZ News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
MYNZ News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MYNZ News From Around the Web
Below are the latest news stories about MAINZ BIOMED NV that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.
Mainz Biomed partners with Quest for colorectal cancer screening testThe test leverages PCR technology to detect cancerous DNA in stool samples. |
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening TestQuest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to support commercialization of Mainz B |
Mainz Biomed Announces Closing of $8.0 Million Follow-On OfferingBERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Class A warrant to purchase one ordinary share, and one Class B warrant to purchase one o |
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq RulesBERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 1,367,521 units, with each unit consisting of one ordinary share (or prefunded warrant in lieu thereof) one Series A warrant to purchase one ordinary share, and one series B warrant to purchase one ordinary share for gro |
Mainz Biomed Announces Stock SplitBERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The r |
The Oncology Bet Is Already Paying Off For PfizerWith the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to approved cancer products from Seagen it acquired last December. On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch of its updated Covid-19 vaccine earlier this year as focused on slashing costs. |
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global MarketsBERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. The collaboration agreement will enable Mainz B |
Mainz Biomed restructured operations, implemented cost reductionsIn September 2024, Mainz Biomed (MYNZ) announced feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with additional average risk population. In October 2024, the Company made the strategic decision to focus its efforts on three key initiatives for the remainder of 2024 and into 2025 in order to maximize shareholder value. Those initiatives are: The continued growth of its ColoAlert business in Europe; Development of its |
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateRevenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular g |
Mainz Biomed Secures Additional $1.5M FundingMainz Biomed B.V. (MYNZ) has released an update. Mainz Biomed B.V. has entered into a supplemental agreement with YA II PN, LTD. for a fourth Pre-Paid Advance of $1.5 million, following three previous promissory notes totaling $14.3 million. The funds from this latest note are designated for working capital and general corporate purposes, ensuring the company’s continued operations without shareholder approval for issuance. The transaction is exempt from registration under the Securities Act, in |